Mycobacterium tuberculosis (Mtb) is the bacterial pathogen responsible for tuberculosis (TB), a deadly disease that kills more than one million people worldwide each year. Current treatment protocols rely heavily on antibiotics developed in the 1950s and 1960s. As a direct consequence of this outdated therapeutic approach, drug resistance has become alarmingly widespread, creating an urgent demand for innovative drug targets.
Our research programme is dedicated to identifying previously unknown Mtb metabolites and enzymes that could serve as promising new drug targets. To uncover novel enzymes and metabolic pathways that play crucial roles in disease progression, we employ an integrated approach that combines traditional biochemical methods with cutting-edge omics technologies.
